Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action

Pharmacology Biochemistry and Behavior

Volumn 87, Issue 4, 2007, Pages 453-461

  Marona Lewicka, Danuta ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT1A; 5 HT2A; Delayed temporal phase; Dopamine; Dopamine D1; Dopamine D2; Dopamine D4; Drug discrimination; GABA; GABAB; LSD; Rats

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ABT 724; AMINE; AMPHETAMINE; ARIPIPRAZOLE; BACLOFEN; COCAINE; DIHYDREXIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; LISURIDE MALEATE; LYSERGIDE; MESCALINE; META CHLOROPHENYLPIPERAZINE HYDROCHLORIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N,N DIETHYLTRYPTAMINE; PIPERAZINE DERIVATIVE; PSILOCIN; PSYCHEDELIC AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; RAT; REINFORCEMENT; TASK PERFORMANCE; TEMPORAL CORTEX;

ANIMALS; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION LEARNING; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FOOD; HALLUCINOGENS; LYSERGIC ACID DIETHYLAMIDE; MALE; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS;

ANIMALIA; RATTUS;

EID: 34547838201     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.06.001     Document Type: Article

References (53)

1. Appel J.B., White F.J., and Holohean A.M. Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6 (1982) 529-536
2. Appel J.B., West W.B., Rolandi W.G., Alici T., and Pechersky K. Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 64 (1999) 353-358
3. Appel J.B., West W.B., and Buggy J. LSD, 5-HT (serotonin), and evolution of a behavioral assay. Neurosci Biobehav Rev 27 (2004) 639-901
4. Arnt J. Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats. Pharmacol Toxicol 64 (1989) 165-172
5. Benneyworth M.A., Smith R.L., Barrett R.J., and Sanders-Bush E. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice. Psychopharmacology 179 (2005) 854-862
6. Blair J.B., Kurrasch-Orbaugh D., Marona-Lewicka D., Cumbay M.G., Watts V.J., Barker E.L., et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 43 (2000) 4701-4710
7. Brebner K., Phelan R., and Roberts D.C.S. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology 148 (1999) 314-329
8. Callahan P.M., and Appel J.B. Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure. Psychopharmacology 100 (1990) 13-18
9. Campbell U.C., Lac S.T., and Carroll M.E. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology 143 (1999) 209-214
10. 4 receptor agonist. Psychopharmacology 188 (2006) 244-251
11. Chemel B.R., Roth B.L., Armbruster B., Watts V.J., Marona-Lewicka D., and Nichols D.E. The "selective" 5-HT1A antagonist WAY-100635 and its metabolite, WAY-100634, are potent dopamine D4 receptor agonists. ACNP, 45th annual meeting ; Dec 3-7 (2006) Hollywood, FL
12. Chojnacka-Wojcik E., and Klodzinska A. Involvement of 5-hydroxytryptamine 2A (5-HT2A) receptors in the mediation of the discriminative stimulus properties of (±)DOI in rats. Pol J Pharmacol 49 (1997) 299-304
13. Colpaert F.C. Cross generalization with LSD and yohimbine in the rat. Eur J Pharmacol 102 (1984) 541-544
14. Colpaert F.C. Drug discrimination in neurobiology. Pharmacol Biochem Behav 64 (1999) 337-345
15. Colpaert F.C., and Janssen P.A. A characterization of LSD-antagonist effects of pirenperone in the rat. Neuropharmacology 22 (1983) 1001-1005
16. Colpaert F.C., Niemegeers C.J., and Janssen P.A. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther 221 (1982) 206-214
17. Colpaert F.C., Meert T.F., Niemegeers C.J., and Janssen P.A. Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 86 (1985) 45-54
18. Cunningham K.A., and Appel J.B. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology 91 (1987) 67-73
19. Cunningham K.A., Callahan P.M., and Appel J.B. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD. Eur J Pharmacol 108 (1985) 179-186
20. 2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives. Psychopharmacology 121 (1995) 357-363
21. Freedman D.X. LSD: the bridge from human to animal. In: Jacobs B.L. (Ed). Hallucinogens: neurochemical, behavioral, and clinical perspectives (1984), Raven Press, New York 203-226
22. Freedman D.X. Hallucinogenic drug research-if so, so what? Symposium summary and commentary. Pharmacol Biochem Behav 24 (1986) 407-415
23. Hofmann A. How LSD originated. J Psychedelic Drugs 11 (1979) 53-60
24. Huang X., Marona-Lewicka D., Pfaff R.C., and Nichols D.E. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol Biochem Behav 47 (1994) 667-673
25. Jayaram P., and Steketee J.D. Effects of repeated cocaine on medial prefrontal cortical GABABreceptor modulation of neurotransmission in the mesocorticolimbic dopamine system. J Neurochem 90 (2004) 839-847
26. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96 (1949) 99-112
27. Marona-Lewicka D., and Nichols D.E. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 258 (1994) 1-13
28. 2-adrenoceptor agonist and antagonists. Psychopharmacology 120 (1995) 384-391
29. Marona-Lewicka D., Thisted R.A., and Nichols D.E. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology 180 (2005) 427-435
30. Minnema D.J., Hendry J.S., and Rosecrans J.A. Discriminative stimulus properties of pizotifen maleate (BC105): a putative serotonin antagonist. Psychopharmacology 83 (1984) 200-204
31. Monte A.P., Waldman S.R., Marona-Lewicka D., Wainscott D.B., Nelson D.L., Sanders-Bush E., et al. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 40 (1997) 2997-3008
32. Monte A.P., Marona-Lewicka D., Parker M.A., Wainscott D.B., Nelson D.L., and Nichols D.E. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39 (1996) 2953-2961
33. Munzar P., Kutkat S.W., Miller C.R., and Goldberg S.R. Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine. Eur J Pharmacol 408 (2000) 169-174
34. Nichols D.E. Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol Biochem Behav 24 (1986) 335-340
35. Nichols D.E., Frescas S., Marona-Lewicka D., and Kurrasch-Orbaugh D.M. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem 45 (2002) 4344-4349
36. Oberlender R.A., Kothari P.J., Nichols D.E., and Zabik J.E. Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. J Med Chem 27 (1984) 788-792
37. Pehek E.A., Nocjar C., Roth B.L., Byrd T.A., and Mabrouk O.S. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31 (2006) 265-277
38. Rabin R.A., Regina M., Doat M., and Winter J.C. 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72 (2002) 29-37
39. Reissig C.J., Eckler J.R., Rabin R.A., and Winter J.C. The 5-HT(1A) receptor and the stimulus effects of LSD in the rat. Psychopharmacology 182 (2005) 197-204
40. Roberts D.C., and Andrews M.M. Baclofen suppression of cocaine self-administration: demonstration using a discrete trails procedure. Psychopharmacology 131 (1997) 271-277
41. Roberts D.C., Andrews M.M., and Vickers G.J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 15 (1996) 417-423
42. Sandoval M.R., and Palermo-Neto J. Effects of manipulation of the GABA system on dopamine-releated behaviors. Braz J Med Res 28 (1995) 88-99
43. Shoaib M., Swanner L.S., Beyer C.E., Goldberg S.R., and Schindler C.W. The GABA-B agonist baclofen modifies cocaine self-administration in the rats. Behav Pharmacol 9 (1998) 195-206
44. Smith R.L., Barrett R.J., and Sanders-Bush E. Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(±)DOI] in C57BL/6J mice. Psychopharmacology 166 (2003) 61-68
45. Steiniger B., and Kretschmer B.D. Glutamate and GABA modulate dopamine in the pedunculopontine tegmental nucleus. Exp Brain Res 149 (2003) 422-430
46. Titeler M., Lyon R.A., and Glennon R.A. Radioligand binding evidence implicates the brain 5-HT2 receptors as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94 (1988) 213-216
47. Vollenweider F.X., Leenders K.L., Schafetter C., Maguire P., Stadelman O., and Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocibin model of psychosis. Neuropsychopharmacology 16 (1997) 357-372
48. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bablar A., Vogel H., and Hell D. Psilocibin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. NeuroReport 9 (1998) 3897-3902
49. Westerink B.H., Kwint H.F., and De Vries J.B. The pharmacology of mesolimbic dopamine neurons: a dual probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16 (1996) 2605-2611
50. White F.J. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol Biochem Behav 24 (1986) 365-379
51. Xi Z.X., and Stein E.A. Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther 290 (1999) 1369-1374
52. Young R., Rosecrans J.A., and Glennon R.A. Comparative stimulus effects of 5-methoxydimethyltryptamine and LSD. Life Sci 30 (1982) 2057-2062
53. Zar J.H. Biostatistical anaysis. 4th edn. (1999), Prentice-Hall, New York